Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an update.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in an international multicentre phase 2 clinical study of HLX43, an anti-PD-L1 antibody-drug conjugate, for advanced non-small cell lung cancer in mainland China. This study aims to evaluate the efficacy and safety of HLX43, with the primary endpoint being the objective response rate. The phase 1 clinical trial results showed promising safety profiles and anti-tumor activity, particularly in non-small cell lung cancer and thymic squamous cell carcinoma, indicating potential positive implications for the company’s market positioning and stakeholders.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company focused on developing innovative biologic drugs, particularly in the field of oncology. The company specializes in antibody-drug conjugates and has a strong market focus on advanced and metastatic solid tumors, including non-small cell lung cancer.
Average Trading Volume: 1,429,186
Technical Sentiment Signal: Buy
Current Market Cap: HK$24.78B
For an in-depth examination of 2696 stock, go to TipRanks’ Stock Analysis page.